Redwire Pioneering Biopharma Production in Space by Successfully Bioprinting Live Human Heart Tissue and Delivering Second Batch of PIL-BOX Pharmaceutical Crystal Experiments
Redwire (NYSE: RDW) successfully 3D bioprinted live human heart tissue on the International Space Station, marking a significant advancement in space biotech capabilities. The company also delivered a second batch of pharmaceutical crystal experiments from its PIL-BOX platform. The bioprinting of heart tissue and crystal experiments in microgravity opens up new possibilities for drug discovery and development, potentially leading to more effective treatments for patients. Redwire's partnership with Eli Lilly and Co. highlights its commitment to advancing space biotech capabilities.
Successful 3D bioprinting of live human heart tissue on the International Space Station.
Delivery of a second batch of pharmaceutical crystal experiments from Redwire's PIL-BOX platform.
Potential for creating heart patches for damaged tissue and personalized medicine using bioprinted heart tissue.
Opportunities for drug discovery and development through crystal growth in microgravity.
Partnership with Eli Lilly and Co. for spaceflight investigations, showcasing the company's commitment to innovation.
Potential challenges in scaling up bioprinting and crystal experiments for commercial production.
Risks associated with the reliability and consistency of manufacturing pharmaceutical crystals in space.
Live human heart tissue bioprinted with Redwire's BioFabrication Facility onboard the International Space Station. The tissue successfully returned to Earth in April 2024. Image: Redwire
Redwire’s space biotech capabilities are creating valuable opportunities for the biopharma industry as microgravity allows for outcomes that aren’t possible on Earth, including bioprinting materials that form and hold a three-dimensional shape without the use of scaffolds or additional chemical support. It is also possible to grow larger and more-highly-ordered pharmaceutical crystals in microgravity. Understanding crystal growth and design can inform the entire drug discovery, development, and design process for small molecule and large biomolecule pharmaceuticals as companies look to deliver new, optimized treatments to help patients.
“These are extraordinary scientific achievements that bring us closer to reliable, large-scale commercial biotech services on-orbit,” said Redwire In-Space Industries President John Vellinger. “With BFF and PIL-BOX, Redwire has leveraged decades of spaceflight heritage to position itself as a market leader for space biotech capabilities and is now setting the pace for on-orbit contract development and production.”
Live human heart tissue bioprinted on Redwire’s BFF could eventually be used to create heart patches as a treatment for damaged heart tissue and opens the door to more effective, personalized medicine. The tissue sample is now undergoing further testing at Redwire’s facility in
Redwire’s second batch of returned PIL-BOX experiments comprised of 36 crystal experiments, which included various crystal molecules designed for pharmaceutical use, with antiviral, antifungal, and antiseizure applications. These returned crystal experiments were led by Redwire and Butler University.
Redwire recently partnered with Eli Lilly and Co. for a second spaceflight investigation, which launched in March 2024. The Lilly crystal experiments are expected to return to Earth in a Dragon capsule onboard the Crew-8 mission which is currently targeting August 2024. There are 16 upcoming investigations planned for PIL-BOX, with samples launching to the ISS and returning to Earth on every upcoming commercial resupply mission.
The PIL-02 and PIL-03 investigations have validated Redwire’s ability to consistently provide pharmaceutical researchers with a reliable platform to manufacture a variety of crystals in space and bring them down quickly in a repeatable and scalable process.
BFF and PIL-BOX are part of Redwire’s expansive array of space biotech and microgravity development platforms that make use of the space environment to improve life on Earth. Redwire has developed 20 research facilities for crewed spacecraft, with 10 currently aboard the ISS supporting world-leading research and manufacturing missions.
About Redwire
Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire’s proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire’s approximately 700 employees, working from 14 facilities located throughout
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507667003/en/
Emily Devine
Emily.Devine@redwirespace.com
305-632-9137
OR
Investors:
investorrelations@redwirespace.com
904-425-1431
Source: Redwire Corporation
FAQ
What scientific achievement did Redwire announce recently related to biopharma production in space?
What is the stock symbol for Redwire ?
Who is Redwire's partner for crystal experiments in space?
Where is the live human heart tissue sample undergoing testing?
What are the potential applications of the crystal experiments delivered by Redwire's PIL-BOX platform?
